Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Summary: Retatrutide dosage for weight loss in clinical trials follows a stepwise escalation from 12 mg subcutaneously once weekly up to maintenance doses of 4 mg, 8 mg, or 12 mg, though the medicine is not yet approved for use in the UK
If you experience any of these symptoms, contact your healthcare provider immediately
Framing weight management as a shared, long-term plan can help patients feel supported and prepared for the next phase of care
piktogramok High active agent contentA product with an extra high amount of active agents
Important safety considerations include the risk of hypoglycemia when tirzepatide is used in combination with insulin or sulfonylureas (requiring dose adjustments of these medications), potential thyroid C-cell tumor risk (contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), and the possibility of acute pancreatitis
